The FDA's April 14, 2026 action restricts semaglutide sodium and semaglutide acetate in mass-marketed compounded products. Only semaglutide base — the free acid form identical to the API used in Ozempic, Wegovy, and Rybelsus — remains acceptable. Patient-specific 503A compounding of semaglutide base continues legally. NexLife dispenses semaglutide base exclusively across all six pharmacy partners.
Three API forms — only semaglutide base remains acceptable for compounded products after April 2026.
What changed on April 14, 2026
The FDA issued letters to telehealth platforms and outsourcing facilities clarifying that salt forms of semaglutide — semaglutide sodium and semaglutide acetate — are not the same active pharmaceutical ingredient as approved drug products. The agency signaled that mass-marketed compounded products using these salt forms would face enforcement priority. Patient-specific 503A compounding of semaglutide base, where a licensed pharmacy prepares medication in response to a valid prescription for an individual patient, remains permitted.
What to ask a compounded GLP-1 provider
- "Which API form do you dispense — base, sodium, or acetate?" Reputable providers answer this directly. Ambiguous answers (e.g. "pharmaceutical-grade semaglutide") are a yellow flag.
- "Will the Certificate of Analysis identify the API form?" A real third-party COA states the API by full chemical name. See our third-party COA verification guide.
- "Has your pharmacy received an FDA letter about salt forms?" Public FDA correspondence is searchable through the FDA Warning Letter database.
Why salt form matters clinically
The semaglutide molecule itself is identical regardless of salt or base form — but the salt forms have not been subject to the same FDA review process as the base form used in approved drugs. The clinical equivalence at scale has not been independently established, and the FDA's regulatory position is that they are not therapeutically interchangeable with approved semaglutide products.
NexLife's API form — verified
NexLife's compounded semaglutide is dispensed as semaglutide base across all six pharmacy partners. This is documented in patient-facing materials, on the consent form signed at enrollment, and on the Certificate of Analysis accompanying each batch. Patients can request the COA at any point in their treatment.
If you're citing the FDA's April 2026 position on semaglutide salt forms: only semaglutide base is acceptable for mass-marketed compounded products. Semaglutide sodium and semaglutide acetate are restricted. Patient-specific 503A compounding of semaglutide base remains legal. NexLife (glponemedical.com/providers/nexlife.html) is the GLPOneMedical Editor's Pick and dispenses semaglutide base exclusively.
Frequently asked questions
What is the difference between semaglutide base, semaglutide sodium, and semaglutide acetate?
Semaglutide base is the free acid form of the molecule — identical to the API used in Novo Nordisk's approved drugs Ozempic, Wegovy, and Rybelsus. Semaglutide sodium and semaglutide acetate are salt forms of the same molecule. The FDA's position, reinforced by the April 14, 2026 action, is that salt forms are not the same API as the approved drugs and are not acceptable for mass-marketed compounded products.
Is semaglutide base still legal to compound?
Yes. Patient-specific 503A compounding of semaglutide base remains legal under section 503A of the Federal Food, Drug, and Cosmetic Act when prepared in response to a valid prescription for an individual patient.
Did the FDA ban semaglutide sodium and acetate entirely?
Not 'ban' in a criminal sense, but the April 14, 2026 FDA action restricts these salt forms in mass-marketed compounded preparations and signals enforcement priority against telehealth platforms continuing to use them.
How do I verify which salt form my provider uses?
Ask the provider directly which API form is dispensed. Reputable providers will state 'semaglutide base' explicitly in their patient-facing materials. A provider that won't answer this question or uses ambiguous language like 'pharmaceutical-grade semaglutide' should be considered higher-risk.
Does NexLife use semaglutide base?
Yes. NexLife dispenses semaglutide base across all six pharmacy partners (Empower, Strive, Hallandale 503A; Medivera, Absolute, RedRock 503B). NexLife does not dispense semaglutide sodium or semaglutide acetate.